AbbVie Inc (ABBV) Position Increased by Sullivan Bruyette Speros & Blaney LLC

Sullivan Bruyette Speros & Blaney LLC boosted its holdings in shares of AbbVie Inc (NYSE:ABBV) by 7.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 16,980 shares of the company’s stock after purchasing an additional 1,110 shares during the quarter. Sullivan Bruyette Speros & Blaney LLC’s holdings in AbbVie were worth $1,565,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in AbbVie by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 118,762,307 shares of the company’s stock valued at $11,232,540,000 after acquiring an additional 912,625 shares in the last quarter. Vanguard Group Inc raised its holdings in AbbVie by 0.8% in the 3rd quarter. Vanguard Group Inc now owns 118,762,307 shares of the company’s stock valued at $11,232,540,000 after acquiring an additional 912,625 shares in the last quarter. Capital International Investors raised its holdings in AbbVie by 266.4% in the 3rd quarter. Capital International Investors now owns 27,594,648 shares of the company’s stock valued at $2,609,902,000 after acquiring an additional 20,063,435 shares in the last quarter. Capital World Investors raised its holdings in shares of AbbVie by 74.9% in the 3rd quarter. Capital World Investors now owns 25,359,025 shares of the company’s stock worth $2,398,457,000 after buying an additional 10,858,432 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of AbbVie by 2.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 15,879,753 shares of the company’s stock worth $1,501,907,000 after buying an additional 382,597 shares in the last quarter. Hedge funds and other institutional investors own 70.66% of the company’s stock.

A number of brokerages have recently issued reports on ABBV. Zacks Investment Research cut AbbVie from a “hold” rating to a “sell” rating in a report on Friday, April 5th. Argus cut AbbVie from a “buy” rating to a “hold” rating in a report on Monday, March 25th. ValuEngine raised AbbVie from a “strong sell” rating to a “sell” rating in a report on Friday, March 15th. Barclays reissued a “hold” rating and issued a $86.00 target price on shares of AbbVie in a report on Thursday, February 14th. Finally, Credit Suisse Group set a $79.00 target price on AbbVie and gave the stock a “hold” rating in a report on Friday, January 25th. Six equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $94.48.

In other news, VP Brian L. Durkin sold 475 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $79.69, for a total value of $37,852.75. Following the transaction, the vice president now directly owns 9,121 shares in the company, valued at approximately $726,852.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Azita Saleki-Gerhardt sold 15,797 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $79.03, for a total value of $1,248,436.91. Following the sale, the executive vice president now directly owns 93,312 shares in the company, valued at approximately $7,374,447.36. The disclosure for this sale can be found here. Insiders sold a total of 41,272 shares of company stock worth $3,286,290 over the last 90 days. 0.08% of the stock is owned by corporate insiders.

NYSE:ABBV opened at $80.78 on Monday. AbbVie Inc has a 12-month low of $75.77 and a 12-month high of $107.25. The firm has a market capitalization of $119.16 billion, a PE ratio of 10.21, a P/E/G ratio of 1.68 and a beta of 1.16.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, January 25th. The company reported $1.90 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.92 by ($0.02). AbbVie had a negative return on equity of 439.07% and a net margin of 17.36%. The company had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter in the prior year, the business earned $1.48 earnings per share. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. On average, research analysts anticipate that AbbVie Inc will post 8.69 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be given a $1.07 dividend. The ex-dividend date of this dividend is Friday, April 12th. This represents a $4.28 annualized dividend and a dividend yield of 5.30%. AbbVie’s dividend payout ratio is currently 54.11%.

ILLEGAL ACTIVITY WARNING: “AbbVie Inc (ABBV) Position Increased by Sullivan Bruyette Speros & Blaney LLC” was first reported by WKRB News and is owned by of WKRB News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.wkrb13.com/2019/04/15/abbvie-inc-abbv-position-increased-by-sullivan-bruyette-speros-blaney-llc.html.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

See Also: What are the components of an earnings report?

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.